1. 2019 CDEC Meeting Schedule Released
   • A new schedule format includes submission deadlines and guidance on when manufacturers can expect embargoed and final recommendations.
2. Updated Advance Notification Form (effective immediately)
   • New form includes an acknowledgement that information provided in the form may be shared with federal, provincial and territorial governments, their agencies and departments and the pan-Canadian Pharmaceutical Alliance.
3. Patient groups who provide input to be identified in product’s Key Milestone table online
   • Applies to CDR submissions and resubmissions received on or after July 2, 2018.
4. CDR-participating drug plans may attend pre-submission meetings (effective immediately)
5. Updated CDR Submission Guidelines & Procedures documents to be published June 2018
   A preview of key changes include:
   
   • Category 1 Requirements:
     • Cover letter requirements to be reduced
     • New consolidated template for letters
     • No longer required: Literature Search Strategy, CONSORT Diagrams and Health Canada reviewers report
   • Category 2 Requirements:
     • No longer required: Certified Product Information Document (CIPD)
     • Filing date will be ≤ 20 business days from the date accepted for review (instead of ≤ 20 business days prior to target CDEC meeting)
     • Cover Letter is no longer required
   • Therapeutic review process revisions:
     • to include reassessment of existing CDEC recommendations

For more information, please consult the CDR Update 136 Newsletter.